50 results
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
7 May 24
Rhythm Pharmaceuticals Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
7:10am
in the United States.
R&D Expenses: R&D expenses were $128.7 million for the three months ended March 31, 2024, as compared to $37.9 million for the three … , inclusive of:
SG&A expenses of $105 million to $110 million; and
R&D expenses of $145 million to $160 million,
inclusive of $10 million to $15 million
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
22 Feb 24
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
7:01am
of the license revenue.
R&D Expenses: R&D expenses were $29.9 million in the fourth quarter of 2023 and $135.0 million for the year ended December 31, 2023 … are derived from:
GAAP total operating expenses, inclusive of:
SG&A expenses of $105 million to $110 million; and
R&D expenses of $145 million
8-K
EX-99.1
lvd j94zqtkb6g6t
7 Nov 23
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
qice0kd38
1 Aug 23
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business
7:05am
8-K
EX-99.1
ufs097qihc1aqx 45
2 May 23
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
c2m40x 2pyclw7r5pyp
8 Nov 22
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
7:03am
8-K
EX-99.1
hi4wg8p96o8n7qga1xz
2 Aug 22
Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update
7:02am
8-K
EX-99.1
3v2zyj
3 May 22
Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update
7:05am
8-K
EX-99.1
cqhn6h 4n2cp
2 Nov 21
Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results
7:05am